STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia

NCT00015834 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

46

Enrollment

NIH

Sponsor class

Conditions

Blastic Phase Chronic Myelogenous Leukemia
Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Relapsing Chronic Myelogenous Leukemia

Interventions

DRUG: imatinib mesylate
DRUG: cytarabine

Sponsor

National Cancer Institute (NCI)